These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 21217522)

  • 1. Insulin-like growth factor receptor-1 (IGF-1R) expression in normal breast, proliferative breast lesions, and breast carcinoma.
    Bhargava R; Beriwal S; McManus K; Dabbs DJ
    Appl Immunohistochem Mol Morphol; 2011 May; 19(3):218-25. PubMed ID: 21217522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
    Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
    Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.
    Bhargava R; Beriwal S; Dabbs DJ; Ozbek U; Soran A; Johnson RR; Brufsky AM; Lembersky BC; Ahrendt GM
    Cancer; 2010 Mar; 116(6):1431-9. PubMed ID: 20131351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial.
    Singh B; Smith JA; Axelrod DM; Ameri P; Levitt H; Danoff A; Lesser M; de Angelis C; Illa-Bochaca I; Lubitz S; Huberman D; Darvishian F; Kleinberg DL
    Breast Cancer Res; 2014 Nov; 16(6):463. PubMed ID: 25385439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue.
    Chong YM; Colston K; Jiang WG; Sharma AK; Mokbel K
    Breast Cancer Res Treat; 2006 Oct; 99(3):275-88. PubMed ID: 16752221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients.
    Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Wauters CA; Strobbe LJ; Mandigers CM; Bult P; Oyen WJ; van der Graaf WT; van Laarhoven HW
    PLoS One; 2015; 10(2):e0117745. PubMed ID: 25680198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
    Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus.
    Kalinina T; Bockhorn M; Kaifi JT; Thieltges S; Güngör C; Effenberger KE; Strelow A; Reichelt U; Sauter G; Pantel K; Izbicki JR; Yekebas EF
    Int J Cancer; 2010 Oct; 127(8):1931-40. PubMed ID: 20104520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer.
    Köstler WJ; Hudelist G; Rabitsch W; Czerwenka K; Müller R; Singer CF; Zielinski CC
    J Cancer Res Clin Oncol; 2006 Jan; 132(1):9-18. PubMed ID: 16184380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor-1 receptor expression in thymic malignancies.
    Girard N; Teruya-Feldstein J; Payabyab EC; Riely GJ; Rusch VW; Kris MG; Zakowski MF
    J Thorac Oncol; 2010 Sep; 5(9):1439-46. PubMed ID: 20736806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
    Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S
    Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of pathologic complete response after standard neoadjuvant chemotherapy in triple-negative breast carcinoma.
    Kraus JA; Beriwal S; Dabbs DJ; Ahrendt GM; McGuire KP; Johnson RR; Badve P; Puhalla SL; Bhargava R
    Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):334-9. PubMed ID: 22417856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
    Kruger DT; Alexi X; Opdam M; Schuurman K; Voorwerk L; Sanders J; van der Noort V; Boven E; Zwart W; Linn SC
    Int J Cancer; 2020 Apr; 146(8):2348-2359. PubMed ID: 31490549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma.
    Hartog H; Horlings HM; van der Vegt B; Kreike B; Ajouaou A; van de Vijver MJ; Marike Boezen H; de Bock GH; van der Graaf WT; Wesseling J
    Breast Cancer Res Treat; 2011 Oct; 129(3):725-36. PubMed ID: 21107683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folate Receptor Alpha Immunohistochemistry in Cytology Specimens of Metastatic Breast Carcinoma.
    Sheikh UN; Cohen C; Siddiqui MT
    Acta Cytol; 2015; 59(4):298-304. PubMed ID: 26413911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
    Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
    J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors.
    Di Modugno F; Mottolese M; Di Benedetto A; Conidi A; Novelli F; Perracchio L; Venturo I; Botti C; Jager E; Santoni A; Natali PG; Nisticò P
    Clin Cancer Res; 2006 Mar; 12(5):1470-8. PubMed ID: 16533770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes.
    Yerushalmi R; Gelmon KA; Leung S; Gao D; Cheang M; Pollak M; Turashvili G; Gilks BC; Kennecke H
    Breast Cancer Res Treat; 2012 Feb; 132(1):131-42. PubMed ID: 21574055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.